China readies biotech export curbs as US weighs investment limits

China is collecting comments until Nov. 15 on revisions to its export control catalogue covering 40 technologies in AI, biopharma and solar power. Two biotech technologies face export bans, including cell and gene therapy platforms, while the US Congress is advancing the BINSA bill to screen biotech investment in China.

• China's catalogue covers 40 technologies across AI, biopharma and solar
• Two biotech technologies proposed for export ban, including cell and gene therapy platforms
• Three technologies restricted, including LNP delivery and CRISPR vector production
• US BINSA bill would subject biotech investment in China to Treasury review